May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
A Randomized Cross-Over Study Comparing Bimatoprost and Latanoprost in Patients With Primary Angle Closure Glaucoma
Author Affiliations & Notes
  • S. K. Seah
    Glaucoma, Singapore National Eye Centre, Singapore, Singapore
  • A. C. How
    Glaucoma, Singapore National Eye Centre, Singapore, Singapore
  • R. S. Kumar
    Glaucoma, Singapore National Eye Centre, Singapore, Singapore
  • Y.-M. Chen
    Clinical Trials and Epidemiology Research Unit, Singapore, Singapore, Singapore
  • D. Su
    Glaucoma, Singapore National Eye Centre, Singapore, Singapore
  • F. T. Oen
    Glaucoma, Singapore National Eye Centre, Singapore, Singapore
  • T. Aung
    Glaucoma, Singapore National Eye Centre, Singapore, Singapore
  • Footnotes
    Commercial Relationships  S.K. Seah, None; A.C. How, None; R.S. Kumar, None; Y. Chen, None; D. Su, None; F.T. Oen, None; T. Aung, Allergan, F; Pfizer, C; Alcon, C; Pfizer, R; Allergan, R; Alcon, R.
  • Footnotes
    Support  Unrestricted grant from Allergan
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1217. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. K. Seah, A. C. How, R. S. Kumar, Y.-M. Chen, D. Su, F. T. Oen, T. Aung; A Randomized Cross-Over Study Comparing Bimatoprost and Latanoprost in Patients With Primary Angle Closure Glaucoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1217. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the effect of latanoprost 0.005% once daily with bimatoprost 0.03% once daily in subjects with primary angle closure glaucoma (PACG).

Methods: : This was a prospective randomized 3-month open-label observer-masked cross-over study of 60 PACG subjects who had persistently high IOP despite previous laser iridotomy. All subjects were randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The intraocular pressure (IOP)-reducing effect of the medications were assessed by the reduction in IOP after each medication compared to the baseline. The IOP was measured at 9 am and 5 pm on the baseline, Week 6 and Week 12 visits, and at 9 am on Week 2 and Week 8 visits.

Results: : Fifty-four patients completed both treatment periods and had IOP data available for evaluation. After 6 weeks of treatment, latanoprost reduced IOP (mean ± SD) by 8.4 ± 3.8 mmHg and bimatoprost by 8.9 ± 3.9 mmHg (p=0.23) from a baseline IOP of 25.2 + 3.6 mmHg and 25.2 + 3.6 mmHg respectively. Adverse ocular symptoms and findings were mild in both treatment groups but occurred at a higher frequency in the bimatoprost treated group (p<0.01). Eye redness and ocular irritation were the most frequently reported events in both treated groups. Bimatoprost had better IOP reduction for patients with higher degree of angle closure and greater extent of peripheral anterior synechiae compared to latanoprost.

Conclusions: : In patients with PACG, bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily after 6 weeks of treatment. Both drugs were well tolerated with few ocular adverse events.

Clinical Trial: : www.clinicaltrials.gov NCT00567788

Keywords: intraocular pressure • anterior segment • outflow: trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×